← Leaderboards
Russell F Devore
Vanderbilt University
$1,184
Attributed
$1,184
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,184 · 2
By mechanism
M01$1,184 · 2
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Barney S Graham$269,836
- Nancy Joan Brown$32,445,188
- David Herlie Robertson$14,232,685
- Stephen N. Davis$16,024,395
- Mace L Rothenberg$4,992,407
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationNeoplasm /Cancer ChemotherapyNonsmall Cell Lung CancerClinical ResearchHuman SubjectPaclitaxelClinical Trial Phase ICombination ChemotherapyCis Platinum Compound
Grant awards (10)
6 HYDROXYMETHYLACYLFULVENE IN PATIENTS W/ NON SMALL CELL LUNG CANCER$0
M01 · FY2002 · RR
TAXOL IN PATIENTS W/ ADVANCED NON SMALL CELL LUNG CANCER$0
M01 · FY2002 · RR
TAXOL IN PATIENTS W/ ADVANCED NON SMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
TAXOL IN PATIENTS W/ ADVANCED NON SMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
6 HYDROXYMETHYLACYLFULVENE IN PATIENTS W/ NON SMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
6 HYDROXYMETHYLACYLFULVENE IN PATIENTS W/ NON SMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
6 HYDROXYMETHYLACYLFULVENE IN PATIENTS W/ NON SMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
TAXOL IN PATIENTS W/ ADVANCED NON SMALL CELL LUNG CANCER$0
M01 · FY2001 · RR
TAXOL IN PATIENTS W/ ADVANCED NON SMALL CELL LUNG CANCER$592
M01 · FY2000 · RR
6 HYDROXYMETHYLACYLFULVENE IN PATIENTS W/ NON SMALL CELL LUNG CANCER$592
M01 · FY2000 · RR